Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease.
Cherney DZI, Belmar N, Bjornstad P, Chacko MM, Gunnarsson TP, Hodgin JB, Kretzler M, Pruijm M, Schytz PA, Tuttle KR. Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2025 Oct 30; 40(11):2182-2192.